1202-41-1

Basic information

• Product Name: 3,4-Dihydroxycinnamamide
• Synonyms: 3,4-Dihydroxycinnamamide;2-PropenaMide, 3-(3,4-dihydroxyphenyl)-;3-(3,4-Dihydroxyphenyl)acrylaMide;3-(3,4-Dihydroxyphenyl)
• CAS NO: 1202-41-1
• Molecular Formula: C₉H₉NO₃
• Molecular Weight: 179
• Mol File: 1202-41-1.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3,4-Dihydroxycinnamamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Dihydroxycinnamamide(1202-41-1)
• EPA Substance Registry System: 3,4-Dihydroxycinnamamide(1202-41-1)

Safety Data

• Hazardous Substances Data: 1202-41-1(Hazardous Substances Data)

Usage

Description

3,4-Dihydroxycinnamamide, also known as 3,4-DHCA, is a chemical compound with the molecular formula C9H9NO3. It is a derivative of cinnamic acid and features two hydroxyl groups and an amide group attached to the aromatic ring. These structural features confer upon it antioxidant and potential anti-inflammatory properties, making it a compound of interest in various fields of research and application.

Uses

Used in Pharmaceutical and Nutraceutical Industries:
3,4-Dihydroxycinnamamide is used as a potential therapeutic agent for various conditions due to its antioxidant and anti-inflammatory properties. It is being investigated for its potential applications in the treatment of cancer, Parkinson's disease, and diabetes, where its protective effects against oxidative stress and inflammation could be beneficial.
Used in Cosmetics Industry:
In the cosmetics industry, 3,4-Dihydroxycinnamamide is used as an active ingredient for skin protection and repair. Its antioxidant properties help to combat the harmful effects of free radicals, which can lead to skin aging and damage. Additionally, its potential anti-inflammatory effects may contribute to soothing and healing the skin.
Used in Research:
3,4-Dihydroxycinnamamide is also used in scientific research to explore its biological effects and potential uses further. Studies are being conducted to understand its mechanisms of action and to identify additional therapeutic applications where it may be beneficial.

Upstream product

• 1441337-89-8 C₂₈H₂₃NO₃ 
• 331-39-5 caffeic acid 
• 2345-56-4 Malonamic acid 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 3843-74-1 Methyl caffeate 

Relevant articles and documents

Identification of cinnamic acid derivatives as novel antagonists of the prokaryotic proton-gated ion channel GLIC

Pentameric ligand gated ion channels (pLGICs) mediate signal transduction. The binding of an extracellular ligand is coupled to the transmembrane channel opening. So far, all known agonists bind at the interface between subunits in a topologically conserved "orthosteric site" whose amino acid composition defines the pharmacological specificity of pLGIC subtypes. A striking exception is the bacterial proton-activated GLIC protein, exhibiting an uncommon orthosteric binding site in terms of sequence and local architecture. Among a library of Gloeobacter violaceus metabolites, we identified a series of cinnamic acid derivatives, which antagonize the GLIC proton-elicited response. Structure-activity analysis shows a key contribution of the carboxylate moiety to GLIC inhibition. Molecular docking coupled to site-directed mutagenesis support that the binding pocket is located below the classical orthosteric site. These antagonists provide new tools to modulate conformation of GLIC, currently used as a prototypic pLGIC, and opens new avenues to study the signal transduction mechanism.